GERN — GERON CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886744 ·
Last close
$1.00
Market Cap
$644.24M
52W High
$2.01
52W Low
$0.84
ADV30
14,593,794
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 60,190,000 | 54,139,000 | 5,728,000 | 1,350,000 | 527,106,000 | 69,179,000 | 300,411,000 |
| Jun 2026 | 57,480,000 | 48,240,000 | -12,653,000 | -16,680,000 | 519,009,000 | 62,643,000 | 300,395,000 |
| Mar 2026 | 51,837,000 | 50,145,000 | -236,000 | -3,642,000 | 534,120,000 | 68,895,000 | 305,012,000 |
| Dec 2025 | 48,015,000 | 46,709,000 | -8,508,000 | -28,862,000 | 570,540,000 | 77,560,000 | 344,668,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-90,533,000
Investing CF
$75,386,000
Financing CF
$6,354,000
CapEx
$-629,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.08
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,874,813,000
Inventory
$126,603,000
Receivables
$48,007,000
ST Investments
$217,300,000
EBIT TTM
$-19,037,000
Pretax Income TTM
$-47,834,000
Interest Exp TTM
$28,797,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$217,522,000
EBITDA
$-15,175,000
Free Cash Flow
$-59,214,248
Enterprise Value
$472,416,608
Total Cash
$286,479,008
Total Debt
$121,228,000
Shares Out
644,238,859
Trailing EPS
$-0.08
Book Value
$0.35
ROE
-20.1%
ROA
-1.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 183,881,000 | -51,553,000 | -83,500,000 | 570,540,000 | 344,668,000 | 225,872,000 | -111,037,000 |
| Dec 2024 | 76,994,000 | -173,732,000 | -174,572,000 | 593,781,000 | 313,461,000 | 280,320,000 | -218,618,000 |
| Dec 2023 | 237,000 | -193,944,000 | -184,127,000 | 394,076,000 | 146,127,000 | 247,949,000 | -167,743,000 |
| Dec 2022 | 596,000 | -138,550,000 | -141,901,000 | 190,575,000 | 110,577,000 | 79,998,000 | -127,379,000 |
TTM Snapshot
Revenues TTM
$38,795,000
NetIncome TTM
$-67,612,000
OpCashFlow TTM
—
Assets (Latest)
$519,009,000
Forward EPS
$0.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
| JANX | Janux Therapeutics, Inc. | $655.27M | $10.71 | — |
| OLMA | Olema Oncology, Inc. | $632.52M | $7.22 | — |
| DSGN | Design Therapeutics, Inc. | $630.12M | $9.84 | — |
News headlines (Yahoo Finance, 1h cache)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-18 21:05 · Yahoo
Geron Targets Germany Launch and Deals as RYTELO Sales Grow
2026-11-11 04:14 · Yahoo
What Investors Got Wrong About Geron Before The Drop
2026-11-08 23:15 · Yahoo
Geron: 3 Key Takeaways for Long-Term Investors
2026-11-05 12:14 · Yahoo
Geron Corp (GERN) Q3 2026 Earnings Call Transcript
2026-11-05 03:13 · Yahoo
Geron Corp (GERN) Q3 2026 Earnings Call Highlights: RYTELO Revenue Climbs 27% as Cost Cuts Lift ...
2026-11-04 23:07 · Yahoo
Geron Corporation Q3 2026 Earnings Call Summary
2026-11-04 18:42 · Yahoo
Geron Q3 Earnings Call Highlights
2026-11-04 17:14 · Yahoo
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
2026-11-04 14:00 · Yahoo
Geron (GERN) Reports Break-Even Earnings for Q3
2026-11-04 12:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.